- Home
- ABTS vs KPRX Comparison
ABTS vs KPRX Comparison
Compare ABTS & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | KPRX |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 8.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABTS | KPRX |
|---|---|---|
| Price | $2.00 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 20.8K | ★ 24.2K |
| Earning Date | 04-30-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $1.76 |
| 52 Week High | $10.86 | $4.18 |
Technical Indicators
Market Signals| Indicator | ABTS | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 39.77 |
| Support Level | N/A | $1.96 |
| Resistance Level | $3.00 | $2.21 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.90 | 0.00 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.